Revista de la Asociación Latinoamericana de Diabetes
  Revisiones
Dislipidemia y Diabetes Mellitus tipo 2
  Dr. Felipe Pollak, Dr. Antonio Arteaga y Dra. Valentina Serrano.
« página anterior | 1 | 2 | 3 | 4 | 5 | 6 ver pdf
 

Otros efectos beneficiosos de los hipolipemiantes

Otro aspecto importante de mencionar son los efectos extralipídicos beneficiosos de las estatinas. En el estudio WOSCOPS ("West of Scotland Coronary Prevention Study") la utilización de pravastatina redujo en un 30% el riesgo de presentar DM 2 (p = 0,042)(34). Esta observación ha sido atribuida a los efectos pleiotrópicos y antiinflamatorios de las estatinas, en los mediadores de insulinoresistencia como IL-6 y TNFα . Por otra parte, un metanálisis indica que la utilización de estatinas disminuye la proteinuria y protege la filtración glomerular en los pacientes con enfermedad renal crónica, lo que fue confirmado en el estudio HPS, en el que los pacientes asignados a placebo presentaron un mayor deterioro de su función renal (niveles de creatinina) en comparación al grupo asignado a simvastatina(35)  

Finalmente en el estudio FIELD, el fenofibrato redujo significativamente la progresión de la albuminuria y la indicación de fotocoagulación en la retinopatía. Los mecanismos de estos hallazgos no han sido aclarados y deberán ser confirmados por futuros estudios.


Bibliografía:

1.Haffner S, Letho S, Ronnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2. Diabetes and in non diabetic subjects with prior myocardial infarction. N.Engl.J.Med. 1998; 339: 229.234
2.Whiteley L, Padmanabhan S, Hole D, Isles C. ¿Should Diabetes be considered a Coronary Heart Disease Risk Equivalent? Results from 25 years of follow-up in the Renfrew and Paisley Survey. Diabetes Care. 28: 1588-93, 2005
3.Juutilainen A, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Type 2 Diabetes as a Coronary Heart Disease Equivalent. A 18-year prospective population-based study in Finnish subjects. Diabetes Care. 28 : 2901-07, 2005
4.UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 Diabetes. Lancet. 1998; 317: 703-711.
5.Turner RC, Millns H, Neil HA, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ. 1998, Mar 14; 316(7134): 823-8
6.Siegel RD, Cupples A, Schaefer EJ, Wilson PW. Lipoproteins, apolipoproteins and low-density lipoprotein size among diabetics in the Framingham offspring study. Metabolism. 1996, Oct; 45(10): 1267-72
7.Steiner G. Dyslipoproteinemias of Diabetes.Atherosclerosis. 1994; 110 ( suppl.): S27-33
8.Ziegler O, Guerci B, Candiloros H, Drouin P. Lipoprotein (a) and diabetes mellitus. Diabetes Metab. 1995 Apr; 21 (2): 127-38
9.de Vries R, Perton FG, Dallinga-Thie GM, et al. Plasma cholesteryl ester transfer is a determinant of intima-media thickness in type 2 diabetic and non diabetic subjects: role of CETP and triglycerides. Diabetes. 2005, Dec; 54(12): 3554-9
10.Kolovou GD, Anagnostopoulou KK, Cokkinos DV. Pathophysiology of dyslipidemia in the metabolic syndrome. Postgrad Med 2005; 81: 358-366.
11.Koskinen P, Manttari M, Manninen V, Huttunen JK, Heinonen OP, Frick MH. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care 1992 Jul; 15(7):820-5.
12.Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high density lipoprotein cholesterol. Veteran’s Affair High Density Lipoprotein Cholesterol Intervention Trial (VA-HIT) Study Group. N. Engl. Med. 1999; 341: 410-418.
13.Steiner G, and the Diabetes Atherosclerosis Intervention Study (DAIS). Effect of Fenofibrate on progression of coronary artery disease in type 2 diabetes. A randomized study. Lancet. 2001; 357: 905-910
14.The FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9765 people with type 2 diabetes mellitus (the FIELD study): randomized controlled trial. Lancet 2005; 366: 1849-61
15.Costa J, Borges M, David C, Vaz Carneiro A. Efficacy of lipid lowering drug treatment for diabetic and nondiabetic patients: meta-analysis of randomised trials. BMJ. 2006; 332(7550): 1115-24.
16.Goldberg R, Mellies M, Sacks F, et al. Cardiovascular events and their reduction with Pravastatin in diabetic and glucose intolerant myocardial infarction survivors with average cholesterol levels: subgroup analysis in The Cholesterol and Recurrent Events (CARE) trial. Circulation. 1998; 98: 2513-2519
17.Pyorala K, Pedersen Tr, Kjekhus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with Simvastatin improves prognosis of diabetic patients with coronary heart disease: A subgroup analysis of the 4S study. Diabetes Care. 1997; 20: 614-620
18.Collins R, Armitage J, Parish S, Sleigh P, Peto R,and the Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with Simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003; 361: 2005-2014
19.Colhoun HM, Betteridge DJ, Durrington PN, et al (CARDS study investigators). Primary prevention of cardiovascular disease with Atorvastatin in type 2 Diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomized placebo-controlled trial. Lancet 2004; 364: 685-96
20.Third report of the National Cholesterol Education Program (NCEP) on the detection, evaluation and treatment of high blood cholesterol in adult (ATP III). Executive summary. NIH publication 01-3670, May 2001 (www. nhlbi.nih.gov/guidelines/cholesterol/)
21.American Diabetes Association. Management of dyslipidemia in adults with Diabetes. Diabetes Care. 2003; 26 (suppl.1): S83-86
22.Debacker G. European guidelines on cardiovascular disease prevention in clinical practice. Eur J Cardiov Prev Rehab. 2003; 10: S1-S78.
23.Grundy S, Cleeman J, Merz CN, et al, for the Coordinating Committee of the National Cholesterol Education program. Implications of recent Clinical Trials for the National Education Program Adult Treatment Panel III Guidelines. Circulation 2004; 110: 227-239.
24.Sheperd J, Barter P, Carmena R, et al, for the Treating to new Targets Investigators. Effect of lowering LDL Cholesterol substantially below currently recommended levels in patients with Coronary Heart Disease and Diabetes. The Treating to New Targets ( TNT ) study. Diabetes Care 2006; 29: 1220-26
25.Dunn FL. Management of hyperlipidemia on diabetes mellitus. Endocrinol Metab Clin North Am. 1992 Jun;21(2): 395-414
26.American Diabetes Association. Standars of Medical care in Diabetes. Diabetes Care, 28 (Suppl.1), January 2005: S4-36
27.Buse JB, Tan MH, Prince MJ, Erickson PP. The effects of oral anti-hyperglycemic medications on serum lipid profiles in patients with type 2 diabetes. Diabetes Obes Metab. 2004 Mar; 6(2): 133-56
28.UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998 Sep 12; 352(9131): 854-65
29.Dormandy JA, Charbonnel B, Eckland DJ, et al (PROactive investigators). Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial in macroVascular events): a randomized controlled trial. Lancet 2005; 366: 1279-89
30.Brown BG, Zhao XQ, Chait A, et al. Simvastatin and Niacin, antioxidant vitamins, or the combination for the prevention of Coronary Disease. N Engl J Med. 2001; 345: 1538-39
31.Athyros VG, Papageorgiou AA., Athyrou VV., Demitriadis DS., Kontopoulos AG. Atorvastatin and micronized Fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia. Diabetes Care. 2002; 25: 1198-1202
32.Malcolm Law, Alicja R. Rudnicka. Statin Safety: A Systematic Review. Am Journal of Cardiology. 2006, April; 97(8), Suppl.1: S52-60
33.Gaede P., Vedel P, Larse N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N.Engl.J.Med. 2003; 248: 383-393
34.Freeman D, Norrie J, Sattar N, et al. Pravastatin and the development of Diabetes Mellitus. Evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001; 103: 357- 362
35.Douglas K, O’Malley PG, Jackson JL. Meta-analysis: the effect of statins on albuminuria. Ann Intern Med. 2006 Jul 18;145 (2):117-24.
subir « página anterior | 1 | 2 | 3 | 4 | 5 | 6
  Otros artículos de este número
Influencia de la circunferencia de la cintura sobre la relación entre la presión arterial y la insulina
 Dr. Marino Tagle, Dr. Fausto Gomez, Dra. Andrea Tagle, Dra. María Fernanda Franco, Dra. Lynn Guerrero
 
Ateroesclerosis y Diabetes. Una revisión
 Prof. Dr. Pedro A. Tesone
 
Prader Willi: descripción de un caso clínico
 Dr. Eduardo Contreras Zuñiga, Dr. Andres Felipe Escobar, Dra. Ximena Cardozo
 
Dr. Alfonso Castillo Navarrete (1923 – 2007)
 Docente y Educador Magíster
 
Asociación Latinoamericana de Diabetes